2017 American Transplant Congress
De Novo, Non-Donor Specific HLA Antibodies Are Associated with Inferior Allograft Outcomes After Kidney and Simultaneous Kidney-Pancreas Transplantation.
Introduction: Donor specific antibodies [DSAs] occurring after transplantation are associated with poorer outcomes. However the significance of non-donor directed HLA antibodies [ndHLAs] after transplantation in…2017 American Transplant Congress
Specific Gene Expression Signature of Complement-Activating Donor Specific Anti-HLA Antibody-Mediated Rejection in Kidney Allografts.
Complement-binding anti-HLA DSA have demonstrated higher rejection rate and decreased allograft survival. However, their specific effects on rejection pathogenesis have not been identified. We investigated…2017 American Transplant Congress
Presence of Complement Activating Donor Specific Antibodies Is Associated with Poor Renal Allograft Survival: Two Centre Retrospective Study.
Introduction: Complement fixing donor specific antibodies (DSA) as detected by presence of C3d at the time of rejection is associated with poor graft outcome;no studies…2017 American Transplant Congress
Pre-Operative Desensitization for Live Donor Liver Transplantation with Strong Donor-Specific Antibodies.
Background: Presence of strong donor-specific antibodies (DSA) (MFI>4000) likely results in uncomplicated short-term outcome in whole liver transplants due to absorption of DSA by the…2017 American Transplant Congress
Treating Refractory Liver Allograft Rejection with Photopheresis.
DSAs with persistent high titer alloantibodies are associated with refractory antibody mediated rejection (AMR) and liver injury.METHODS: We present 4 liver transplant (LT) patients refractory…2016 American Transplant Congress
Blockade of HLA Antibody-Triggered Classical Complement Activation by High-Affinity Humanized Monoclonal Anti-C1s Antibody TNT009 – Results of a First-in-Human Phase 1 Trial.
Study purpose: Classical complement may play a key role in ABMR. A promising therapeutic approach could be complement inhibition at the level of key component…2016 American Transplant Congress
Enabled PRA and Precision PRA: Alternatives to cPRA as Desensitization Trial Endpoints.
U of Cincinnati, Cincinnati; Mayo Clinic Scottsdale, Scottsdale.
Transplant (Transplant) rate is an optimal endpoint in desensitization (DS) trials in HLA sensitized Txp candidates, however, for waitlisted Txp candidates, wait time heterogeneity compromises…2016 American Transplant Congress
Comparison of EDTA, DTT and Dilutions to Abrogate the Prozone Effect in Luminex-Based HLA Antibody Assays.
Department of Laboratory Medicine and Pathology, Mayo Clinic, Phoenix, AZ.
Mean fluorescence intensity (MFI) values obtained from Luminex-based single antigen bead (SAB) assays is a semi-quantitative result used to determine the relative strength of HLA…2016 American Transplant Congress
C1q Assays Are Not Associated with Clinical or Serologic Endpoints.
PURPOSE: The c1q assay has been proposed as a potential adjunct to standard donor specific antibody (DSA) testing designed to improve the specificity to identify…2016 American Transplant Congress
Identification of Donor HLA-Specific Antibodies as a Risk Factor for Graft Dysfunction and Failure Following BK Virus Associated Nephropathy.
Transplantation Medicine, Weill Cornell Medicine, New York, NY.
Background: BK virus associated nephropathy (BKVN) has emerged as a significant cause of graft dysfunction and graft failure. Identification of risk factors for graft dysfunction…
- « Previous Page
- 1
- …
- 31
- 32
- 33
- 34
- 35
- …
- 47
- Next Page »